About Conjustar


Tianjin Conjustar Biotechnology Co., Ltd. is located in Tianjin Airport Free Trade Zone, was founded on February 21, 2022, by the Fosun Health Capital and Wuxi Apptec jointly incubated, the seed round financing amount of 45.5 million yuan.

 

Conjustar is committed to developing new miniaturized coupling drugs (polypeptide/nanoantibody coupling drugs, PDC/NDC) to cure solid tumors.

MORE+

Investor Relations

News

MORE+

Technology Platform

Company has the globally excellent technology platform of Development of novel miniaturized conjugated drugs (polypeptide/nanoantibody coupling drugs, PDC/NDC).

MORE+

Pipeline

Focus on core strengths for the benefit of cancer worldwide.

MORE+

Business development and licensing

 

We build strong partnerships to help translate innovations into therapies. Our collaborations have the potential to impact the lives of millions. 

Building strong partnerships

We work with partners, from early-stage science to clinical-stage programs, to deliver new therapies to patients.

MORE+